Table 1 |
||
|
Effects of peroxisome-proliferator-activated receptor γ agonists on viability of IL-1β-stimulated chondrocytes |
||
|
Agonist added |
A580 |
Percentage of control |
|
|
||
|
None (control) |
0.81 ± 0.05 |
100 |
|
IL-1β (10 ng/ml) |
1.12 ± 0.04* |
138 |
|
15d-PGJ2 (10 μM) |
0.91 ± 0.07 |
112 |
|
IL-1β + 15d-PGJ2 |
1.10 ± 0.05 |
135 |
|
Rosiglitazone (10 μM) |
0.95 ± 0.09 |
117 |
|
IL-1β + rosiglitazone |
1.12 ± 0.07 |
138 |
|
|
||
|
15d-PGJ2, 15-deoxy-Δ12,14prostaglandin J2. *, P < 0.05, comparison with non-stimulated controls |
||
|
Bianchi et al. Arthritis Research & Therapy 2005 7:R1325 doi:10.1186/ar1830 |
||
